Structure Therapeutics (Nasdaq: GPCR) is a South San Francisco biotech built on structure-based design of orally available small molecules targeting G-protein-coupled receptors. Its lead asset aleniglipron (GSBR-1290) is the cleanest non-Lilly challenger in the oral GLP-1 race and has emerged as the obesity field's strongest oral non-incretin-peptide candidate outside Foundayo.
The Phase 2b ACCESS program is the data engine. ACCESS II delivered up to 16.3% placebo-adjusted weight loss over 44 weeks, the strongest oral GLP-1 number outside Lilly's orforglipron, with a tolerability profile that held under titration. The full dataset was published in Nature Medicine on June 5, 2026, with a same-day ADA Scientific Sessions oral presentation by Julio Rosenstock. Structure has end-of-Phase-2 FDA alignment and starts Phase 3 in Q3 2026 with a 2.5 mg starting dose, alongside amylin and combination programs. The company has been called out by analysts as a likely acquisition target as Lilly and Novo consolidate the obesity field.
Stories here cover aleniglipron readouts, Structure's broader GPCR pipeline, and the company's market positioning. See #aleniglipron, #access, and #oral-glp-1 for adjacent threads.
On September 8, 2026, Structure reported positive data across both lead programs. Aleniglipron reached 16.2% mean weight loss at 72 weeks in the ACCESS open-label extension at the 180 mg dose, with no observed plateau and fewer than 5% adverse-event discontinuations on the 2.5 mg starting dose. Separately, ACCG-2671 (a first-in-human oral amylin/calcitonin dual agonist) posted a ~6-day half-life supporting once-weekly dosing, a 3.3% body weight reduction 24 days after a single 10 mg dose, and no serious adverse events in 31 healthy volunteers; a 12-week multiple-ascending-dose trial in obese participants is enrolling with topline expected H1 2027.
Structure Therapeutics (NASDAQ: GPCR) reported Tuesday September 8, 2026 positive data across two lead oral small-molecule obesity programs. Aleniglipron (oral small-molecule GLP-1 receptor agonist, formerly GSBR-1290) reached mean 16.2% body weight loss at 72 weeks at the 180 mg dose in the ACCESS Phase 2b open-label extension (11.6% at 45 mg, 14.4% at 90 mg), with no observed weight-loss plateau; fewer than 5% of participants discontinued for adverse events using the improved 2.5 mg starting dose with four-week titration. The Phase 3 ACCOMPLISH program enrolls up to 3,600 adults with obesity plus comorbidity (ACCOMPLISH-1) and up to 1,100 with obesity plus type 2 diabetes (ACCOMPLISH-2), with topline expected H2 2028. Separately, ACCG-2671 (oral small-molecule dual amylin and calcitonin receptor agonist) posted first-in-human Phase 1/2a single-ascending-dose data in 31 healthy volunteers: 3.3% body weight reduction after a single 10 mg dose at Day 24, ~6-day half-life supporting once-weekly dosing, CTX-1 bone resorption biomarker reduction ~60% by Day 2, no serious adverse events, no drug-induced liver injury, no nausea or vomiting at 1-2 mg doses (dose-related GI effects at 5+ mg). A 12-week multiple-ascending-dose trial in obese participants is enrolling with topline expected H1 2027. Despite the data, GPCR shares fell in Tuesday trading on incumbent-class competitive concerns.
Seoul Economic Daily published Monday August 17, 2026 a market synthesis on the obesity drug runner-up field. Key runners-up positioning for 2027-2028 approval filings behind Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO): Structure Therapeutics (NASDAQ: GPCR) with aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist) expected to initiate Phase 3 in H2 2026; Amgen (NASDAQ: AMGN) with MariTide (once-monthly injectable dual GIPR antagonist / GLP-1 agonist) now positioned as the sole obesity focus after the July 29 Q2 disclosure that Amgen halted AMG 513 Phase 1 development to concentrate resources on the MariTide MARITIME Phase 3 program; and Pfizer (NYSE: PFE) with danuglipron oral GLP-1 receptor agonist plus the Metsera acquisition pipeline. Amgen expects to apply for MariTide regulatory approval in late 2026 to early 2027. The Amgen MariTide Phase 3 program covers obesity (MARITIME-1) plus obesity and type 2 diabetes (MARITIME-2), with additional Phase 3 studies exploring cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea. The sorting of winners from losers based on Phase 3 results will begin in earnest starting next year as the field competes on efficacy, safety, delivery format, and price for market share behind Lilly's Zepbound-Mounjaro-Foundayo franchise and Novo's Wegovy-Ozempic franchise.
Structure Therapeutics (NASDAQ: GPCR) reported detailed Phase 2b ACCESS II trial results for aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist for obesity). Key efficacy: 16.3% placebo-adjusted mean weight loss at the 180 mg dose (39 lbs) and 16.0% weight loss at the 240 mg dose (37 lbs) at 44 weeks. This positions aleniglipron as the highest-efficacy oral GLP-1 agonist data reported to date, above Eli Lilly's orforglipron (Foundayo, 7.5-11.2% at 72 weeks in ATTAIN-1) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg, roughly 15% at 68 weeks in OASIS 4). The core Phase 2b ACCESS study had documented 11.3% placebo-adjusted weight loss at 120 mg at 36 weeks. The ACCESS Open-Label Extension (OLE) study documented continued weight loss from 36 weeks up to 16.2% (40.5 lbs) with 120 mg at 56 weeks with no observed plateau, an important tolerability and durability signal. Tolerability profile is consistent with the GLP-1 receptor agonist class with only 3.7% adverse-event-related treatment discontinuation across all active arms in participants who reached 120 mg or higher from weeks 28 to 44. Phase 3 initiation is expected in H2 2026. Aleniglipron is a non-peptide small molecule that binds the GLP-1 receptor, similar to Lilly's orforglipron but distinct from the peptide-based semaglutide and tirzepatide; the small-molecule format provides manufacturing scalability advantages over peptide APIs.
BioSpace's reaction to AstraZeneca's elecoglipron VISTA Phase 2b readout (10.5% weight loss at 26 weeks) framed it as 'relatively underwhelming' next to Structure Therapeutics' aleniglipron (up to 16.3% at 44 weeks, Nature Medicine publication on Friday). Both are oral small-molecule GLP-1s with Phase 3 plans for the second half of 2026, but elecoglipron's lower number gives Structure a clearer differentiation story heading into its Phase 3 start. AstraZeneca will lean on its combination strategy with dapagliflozin and AZD0780 to position elecoglipron.
Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.
Structure Therapeutics will present five obesity and diabetes studies at ADA 2026, anchored by its once-daily oral small-molecule GLP-1 aleniglipron, which posted up to 16.3% placebo-adjusted weight loss at 44 weeks in the Phase 2 ACCESS II trial, among the highest reported for an oral GLP-1. The company has FDA end-of-Phase-2 alignment and plans to start a Phase 3 obesity trial in Q3 2026, with amylin and combination data also on the slate.